Concepedia

Publication | Open Access

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19

DOIFull Paper Access

106

Citations

21

References

2021

Year

Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, Christopher Nelke, Anke Lux, Refik Pul, Christoph Kleinschnitz, Konstanze Kleinschnitz, Rebeca Rogall, Katrin Pape,
Neurology Neuroimmunology & Neuroinflammation

Abstract

This study provides Class IV evidence that for patients with RRMS, an EID of at least 4 weeks does not diminish effectiveness of ocrelizumab.

References

YearCitations

Page 1